Drug Trial Radar · NCT06754930
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Last checked: Nov 19, 2026Latest source record: Apr 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Feb 18, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
SHR-1826Drug
SHR-1826 for injection.
SHR-1316Drug
SHR-1316 for injection.
SHR-9839Drug
SHR-9839 for injection.
SHR-8068Drug
SHR-8068 for injection.
Ametinib mesylateDrug
Ametinib mesylate.
BP-102Drug
BP-102 for injection.
CarboplatinDrug
Carboplatin for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase II dose (RP2D)Time frame: Screening up to study completion, an average of 1 year.
- Adverse events (AEs)Time frame: Screening up to study completion, an average of 1 year.
- Objective response rate (ORR)Time frame: Screening up to study completion, an average of 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.